129 related articles for article (PubMed ID: 38128233)
1. Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.
Singh T; Kim TW; Murthy ASN; Paul M; Sepay N; Jeong Kong H; Sung Ryu J; Rim Koo N; Yoon S; Song KH; Jun Baek M; Jeon S; Im J
Eur J Med Chem; 2024 Feb; 265():116050. PubMed ID: 38128233
[TBL] [Abstract][Full Text] [Related]
2. iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.
Ma L; Chen Q; Ma P; Han MK; Xu Z; Kang Y; Xiao B; Merlin D
Nanomedicine (Lond); 2017 Aug; 12(16):1991-2006. PubMed ID: 28745123
[TBL] [Abstract][Full Text] [Related]
3. Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles.
Jang DJ; Moon C; Oh E
Biomed Pharmacother; 2016 May; 80():162-172. PubMed ID: 27133053
[TBL] [Abstract][Full Text] [Related]
4. A silica-based antioxidant nanoparticle for oral delivery of Camptothecin which reduces intestinal side effects while improving drug efficacy for colon cancer treatment.
Nguyen-Trinh QN; Trinh KXT; Trinh NT; Vo VT; Li N; Nagasaki Y; Vong LB
Acta Biomater; 2022 Apr; 143():459-470. PubMed ID: 35235866
[TBL] [Abstract][Full Text] [Related]
5. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
7. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
Cho HJ; Park SJ; Lee YS; Kim S
J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
[TBL] [Abstract][Full Text] [Related]
8. An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy.
Lu L; Zhao X; Fu T; Li K; He Y; Luo Z; Dai L; Zeng R; Cai K
Biomaterials; 2020 Feb; 230():119666. PubMed ID: 31831222
[TBL] [Abstract][Full Text] [Related]
9. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the tumor-penetrating peptide internalizing RGDÂ for cancer treatment and diagnosis.
Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
[TBL] [Abstract][Full Text] [Related]
11. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
12. Improving Antitumor Activity with N-Trimethyl Chitosan Entrapping Camptothecin in Colon Cancer and Lung Cancer.
Sun L; Li X; Li Z; Li Z; Gou M; Qian Z; Peng F
J Nanosci Nanotechnol; 2015 Sep; 15(9):6397-404. PubMed ID: 26716193
[TBL] [Abstract][Full Text] [Related]
13. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
14. Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy.
Lu L; Li B; Lin C; Li K; Liu G; Xia Z; Luo Z; Cai K
J Mater Chem B; 2020 May; 8(17):3918-3928. PubMed ID: 32227058
[TBL] [Abstract][Full Text] [Related]
15. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
16. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
[TBL] [Abstract][Full Text] [Related]
17. Targeted Delivery of Dual Anticancer Drugs Based on Self-Assembled iRGD-Modified Soluble Drug-Polymer Pattern Conjugate Nanoparticles.
Li C; Chen Z; Zheng D; Zhao J; Lei J
ACS Appl Bio Mater; 2021 Feb; 4(2):1499-1507. PubMed ID: 35014499
[TBL] [Abstract][Full Text] [Related]
18. Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo.
Babaei M; Abnous K; Taghdisi SM; Taghavi S; Sh Saljooghi A; Ramezani M; Alibolandi M
Eur J Pharm Biopharm; 2020 Nov; 156():84-96. PubMed ID: 32882423
[TBL] [Abstract][Full Text] [Related]
19. A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment.
Zhang Q; Zhang F; Li S; Liu R; Jin T; Dou Y; Zhou Z; Zhang J
Theranostics; 2019; 9(13):3732-3753. PubMed ID: 31281510
[TBL] [Abstract][Full Text] [Related]
20. Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer.
Xiao B; Viennois E; Chen Q; Wang L; Han MK; Zhang Y; Zhang Z; Kang Y; Wan Y; Merlin D
ACS Nano; 2018 Jun; 12(6):5253-5265. PubMed ID: 29860836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
